Evidence & Performance Blog

Assessing the performance of CROs

Pharmaceutical and biotech companies want to speed up the research and development process whilst adhering to stricter guidelines. That’s why CRO’s are primarily selected on their scientific expertise and the cost/value ratio.

If R&D companies have always had a ‘feeling’ about their CRO, they are now more and more looking for facts in assessing their performance. This can only be done by “Choosing the right metrics” and “Deploying the right tools to evaluate these metrics”. Read more

ClinPhone, the world’s leading Clinical Technology Organization, will be acquired within the next couple of months.

CRO Parexel already made a $182 million bid, however Quintiles is discussing the acquisition azs well, and if they agree it will most likely be more than what Parexel offers.

Read more